[HLBANK] YoY Cumulative Quarter Result on 30-Jun-2024 [#4]

Announcement Date
29-Aug-2024
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2024
Quarter
30-Jun-2024 [#4]
Profit Trend
QoQ- 32.7%
YoY- 9.9%
View:
Show?
Cumulative Result
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Revenue 5,771,020 5,685,509 5,597,408 5,466,873 4,778,356 4,725,835 4,839,565 2.97%
PBT 5,134,247 4,626,631 4,366,800 3,470,939 2,989,397 3,186,020 3,246,255 7.93%
Tax -938,035 -808,435 -1,077,517 -610,297 -494,800 -521,513 -608,177 7.48%
NP 4,196,212 3,818,196 3,289,283 2,860,642 2,494,597 2,664,507 2,638,078 8.03%
-
NP to SH 4,196,212 3,818,196 3,289,283 2,860,642 2,494,597 2,664,507 2,638,078 8.03%
-
Tax Rate 18.27% 17.47% 24.68% 17.58% 16.55% 16.37% 18.73% -
Total Cost 1,574,808 1,867,313 2,308,125 2,606,231 2,283,759 2,061,328 2,201,487 -5.42%
-
Net Worth 37,280,169 33,988,812 31,006,211 29,461,726 27,221,136 25,472,637 23,893,507 7.68%
Dividend
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Div 1,393,651 1,208,764 1,127,126 1,023,687 736,812 1,022,997 981,924 6.00%
Div Payout % 33.21% 31.66% 34.27% 35.79% 29.54% 38.39% 37.22% -
Equity
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Net Worth 37,280,169 33,988,812 31,006,211 29,461,726 27,221,136 25,472,637 23,893,507 7.68%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
NP Margin 72.71% 67.16% 58.76% 52.33% 52.21% 56.38% 54.51% -
ROE 11.26% 11.23% 10.61% 9.71% 9.16% 10.46% 11.04% -
Per Share
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
RPS 281.58 277.51 273.13 267.02 233.47 230.98 236.58 2.94%
EPS 204.74 186.37 160.60 139.72 121.88 130.23 128.96 8.00%
DPS 68.00 59.00 55.00 50.00 36.00 50.00 48.00 5.97%
NAPS 18.19 16.59 15.13 14.39 13.30 12.45 11.68 7.65%
Adjusted Per Share Value based on latest NOSH - 2,167,718
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
RPS 266.23 262.28 258.22 252.19 220.43 218.01 223.26 2.97%
EPS 193.58 176.14 151.74 131.97 115.08 122.92 121.70 8.03%
DPS 64.29 55.76 52.00 47.22 33.99 47.19 45.30 6.00%
NAPS 17.1979 15.6795 14.3036 13.5911 12.5575 11.7509 11.0224 7.68%
Price Multiplier on Financial Quarter End Date
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Date 28/06/24 30/06/23 30/06/22 30/06/21 30/06/20 28/06/19 29/06/18 -
Price 19.20 18.96 20.46 18.72 14.08 19.00 18.20 -
P/RPS 6.82 6.83 7.49 7.01 6.03 8.23 7.69 -1.97%
P/EPS 9.38 10.17 12.75 13.40 11.55 14.59 14.11 -6.57%
EY 10.66 9.83 7.84 7.46 8.66 6.85 7.09 7.02%
DY 3.54 3.11 2.69 2.67 2.56 2.63 2.64 5.00%
P/NAPS 1.06 1.14 1.35 1.30 1.06 1.53 1.56 -6.23%
Price Multiplier on Announcement Date
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Date 29/08/24 30/08/23 30/08/22 30/08/21 28/08/20 28/08/19 28/08/18 -
Price 21.28 20.00 20.92 19.20 14.00 16.26 20.00 -
P/RPS 7.56 7.21 7.66 7.19 6.00 7.04 8.45 -1.83%
P/EPS 10.39 10.73 13.03 13.74 11.49 12.49 15.51 -6.45%
EY 9.62 9.32 7.67 7.28 8.71 8.01 6.45 6.88%
DY 3.20 2.95 2.63 2.60 2.57 3.08 2.40 4.90%
P/NAPS 1.17 1.21 1.38 1.33 1.05 1.31 1.71 -6.12%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment